Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials

Author(s): Cunlong Zhang, Chunyan Tan, Huaiwei Ding, Tian Xin, Yuyang Jiang

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 20 , 2012

Become EABM
Become Reviewer

Abstract:

Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been explored as a highly successful clinical strategy in cancer treatment. A number of VEGFR inhibitors have been approved in clinical use and many more are in various stages of drug development. This paper reviews selective small-molecule VEGFR inhibitors in clinical uses and in clinical trials, with particular focus on in vitro, in vivo and clinical trial results of these inhibitors. The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.

Keywords: Selective, VEGFR inhibitor, anticancer, angiogenesis, vasculogenesis, tumor growth, metastasis, clinical trials, signaling pathways, growth factors

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 20
Year: 2012
Page: [2921 - 2935]
Pages: 15
DOI: 10.2174/138161212800672732
Price: $65

Article Metrics

PDF: 29